Lv1
20 积分 2023-06-12 加入
Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2–3 study
11天前
已完结
Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study
11天前
已完结
Pattern and predictors of sites of relapse in neuroblastoma: A report from the International Neuroblastoma Risk Group (INRG) project
16天前
已完结
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial
17天前
已完结
First-Line Sugemalimab Plus Chemotherapy for Advanced Gastric Cancer
17天前
已完结
First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trial
17天前
已完结
Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial
18天前
已完结
多学科模式下洛拉替尼不良反应处理专家共识
24天前
已完结
Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC
10个月前
已完结
MetastaticHER2-amplified non-small-cell lung cancer treated with trastuzumab deruxtecan
1年前
已完结
皖公网安备34019202002308
